المؤلفون: Pillai, Nadia, Lupatsch, Judith E, Dusheiko, Mark, Schwenkglenks, Matthias, Maillard, Michel, Sutherland, C Simone, Pittet, Valérie, Swiss IBD Cohort Study group

المساهمون: Petit, Laëtitia Marie

المصدر: Journal of Crohn's and colitis, Vol. 14, No 4 (2020) pp. 490-500

مصطلحات موضوعية: Crohn’s disease, Male, Cost effectiveness, Cost-Benefit Analysis, Disease, Arly biologic initiation, 0302 clinical medicine, Crohn Disease, Quality of life, health care economics and organizations, Biosimilar Pharmaceuticals / economics, Crohn's disease, ddc:618, Gastroenterology, Biosimilar Pharmaceuticals / pharmacology, Biosimilar, General Medicine, Biological Products / economics, 3. Good health, Crohn Disease / economics, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Female, Quality-Adjusted Life Years, Needs Assessment, Switzerland, Adult, medicine.medical_specialty, Crohn Disease / psychology, Biologic treatment, Drug Costs, Time-to-Treatment, 03 medical and health sciences, medicine, Humans, Time-to-Treatment / statistics & numerical data, Intensive care medicine, Biosimilar Pharmaceuticals, Biological Products, business.industry, Time-to-Treatment / economics, Crohn Disease / therapy, medicine.disease, Quality-adjusted life year, Propensity score matching, Quality of Life, Cost-effectiveness, Biological Products / therapeutic use, Crohn Disease / diagnosis, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74f5ee1786efc9d73a19d37360530495
https://archive-ouverte.unige.ch/unige:159485